Effect of short-term prednisone on beta-cell function in subjects with type 2 diabetes mellitus and healthy subjects
Monica Shah, May M Adel, Bettina Tahsin, Yannis Guerra, Leon Fogelfeld, Monica Shah, May M Adel, Bettina Tahsin, Yannis Guerra, Leon Fogelfeld
Abstract
Objective: For those with type 2 diabetes mellitus (T2DM), impact of short-term high-dose glucocorticoid exposure on beta-cell function is unknown. This study aims to compare the impact on beta-cell function and insulin resistance of prednisone 40 mg between adults with newly diagnosed T2DM and healthy adults.
Methods: Five adults with T2DM and five healthy adults, all between 18-50 years, were enrolled. T2DM diagnosis was less than one year prior, HbA1c<75 mmol/mol (9.0%), with metformin treatment only. Pre- and post-therapy testing included 75-g oral glucose tolerance, plasma glucose, C-peptide, and insulin. Intervention therapy was prednisone 40mg daily for 3 days.
Results: Upon therapy completion, HOMA-IR did not increase or differ between groups. Percentile difference for HOMA-%B and insulinogenic index in those with T2DM was significantly lower statistically (50.4% and 69.2% respectively) compared to healthy subjects (19% and 32.2%).
Conclusions: Contrary to the assumption that insulin resistance is the main driver of glucocorticoid-induced hyperglycemia, results indicate that decreased beta-cell insulin secretion is the more likely cause in those with T2DM. This is evidenced by significant drops in C-peptide AUC and HOMA-%B and increased glucose AUC in T2DM group only. These results may be caused by increased beta-cell fragility along with reduced recovery ability after glucocorticoid exposure. ClinicalTrials.gov NCT03661684.
Conflict of interest statement
NO authors have competing interests.
Figures
References
- Onwubalili JK, Obineche EN. High incidence of post-transplant diabetes mellitus in a single-centre study. Nephrol Dial Transplant 1992;7(4):346–349. 10.1093/oxfordjournals.ndt.a092140
- Donihi AC, Raval D, Saul M, Korytkowski MT, DeVita MA. Prevalence and predictors of corticosteroid-related hyperglycemia in hospitalized patients. Endocr Pract 2006. Jul-Aug;12(4):358–362. 10.4158/EP.12.4.358
- Beaudry JL, Riddell MC. Effects of glucocorticoids and exercise on pancreatic beta-cell function and diabetes development. Diabetes Metab Res Rev 2012. October;28(7):560–573. 10.1002/dmrr.2310
- van Raalte DH, Nofrate V, Bunck MC, van Iersel T, Elassaiss Schaap J, Nassander UK, et al. Acute and 2-week exposure to prednisolone impair different aspects of beta-cell function in healthy men. Eur J Endocrinol 2010. April;162(4):729–735. 10.1530/EJE-09-1034
- van Raalte DH, Kwa KA, van Genugten RE, Tushuizen ME, Holst JJ, Deacon CF, et al. Islet-cell dysfunction induced by glucocorticoid treatment: potential role for altered sympathovagal balance? Metabolism 2013. April;62(4):568–577. 10.1016/j.metabol.2012.10.007
- Babu A, Mehta A, Guerrero P, Chen Z, Meyer PM, Koh CK, et al. Safe and simple emergency department discharge therapy for patients with type 2 diabetes mellitus and severe hyperglycemia. Endocr Pract 2009. Nov-Dec;15(7):696–704. 10.4158/EP09117.ORR
- Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985. July;28(7):412–419. 10.1007/bf00280883
- Perez A, Jansen-Chaparro S, Saigi I, Bernal-Lopez MR, Minambres I, Gomez-Huelgas R. Glucocorticoid-induced hyperglycemia. J Diabetes 2014. January;6(1):9–20. 10.1111/1753-0407.12090
- Lambillotte C, Gilon P, Henquin JC. Direct glucocorticoid inhibition of insulin secretion. An in vitro study of dexamethasone effects in mouse islets. J Clin Invest 1997. February 1;99(3):414–423. 10.1172/JCI119175
- Larsson H, Ahren B. Insulin resistant subjects lack islet adaptation to short-term dexamethasone-induced reduction in insulin sensitivity. Diabetologia 1999. August;42(8):936–943. 10.1007/s001250051251
Source: PubMed